Less than two months after life sciences giant Bayer acquired N.C.-based gene therapy company AskBio, the healthcare company launched a cell and gene therapy platform within its pharmaceutical division.
Through a definitive merger agreement, BridgeBio acquired 36.3 percent of Eidos Therapeutics’ outstanding common stock that it did not already own.
Shares of CStone Pharmaceuticals were up after Pfizer invested $200 million into the company for a nearly 10% stake to support the development of a checkpoint inhibitor aimed at the oncology market in China.
TriNet, a leading global health research network optimizing clinical research to bring new therapies to market faster, announced global investment firm The Carlyle Group made a strategic growth investment and will acquire a majority stake in the company.
Gilead Sciences Inc. is nearing a deal to buy biopharmaceutical company Immunomedics Inc. for more than $20 billion in a deal that would further expand Gilead’s portfolio of cancer treatments, the Wall Street Journal reported on Saturday.
GlaxoSmithKline and Germany-based CureVac forged a strategic collaboration worth nearly $1 billion to develop up to five messenger RNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens.
Regeneron Pharmaceuticals will repurchase about $5 billion of the U.S. drugmaker’s shares directly from France’s Sanofi, without altering their 17-year partnership.
The Sumitomo Dainippon-Roivant Alliance encompasses up to 11 biopharmaceutical Vants with more than 25 innovative clinical programs and multiple potential product launches from 2020 to 2022, and access to key elements of Roivant’s proprietary technology platforms including DrugOme and Digital Innovation.
Bayer will cut 12,000 jobs as the company prepares a business overhaul, including an exit from the animal health division.
Nestle’s health science arm will pay $98 million to raise its stake in Aimmune Therapeutics in preparation of submitting a marketing application for the peanut allergy drug AR101 by year-end 2018.